ZDHHC22 and invasive breast carcinoma: zDHHC22 expression was found to be reduced in oestrogen receptor (ER) negative BrCa specimens and cell lines, an effect attributed to the epigenetic methylation of its promoter, and low zDHHC22 expression correlated with good prognosis in BrCa patients.90